MHRA details pilot to cut Phase 1 clinical trial review to 14 days by end of 2026

The Medicines and Healthcare products Regulatory Agency has published detailed guidance for a pilot program meant to cut its initial review time for some Phase 1 clinical trial applications to 14 calendar days by the end of 2026, part of a narrower push to speed lower-risk early-stage studies in the UK.

The guidance, published Aug. 17 and titled “Clinical trials: Phase 1, 14-Day Pilot Programme,” makes clear that this is not an immediate blanket 14-day service for all Phase 1 applications. The MHRA said the pilot launched at the end of March 2026 and is being rolled out in stages, with target first assessment times reduced from 28 calendar days from March 30, to 21 days from June 29, to 18 days from Sept. 28, and finally to 14 days from Dec. 28. The agency said the pilot “aims to deliver the first wave 1 regulatory assessment in 14 calendar days for qualifying applications by the end of 2026.”

Eligibility is tightly drawn. The pilot applies only to Phase 1 trials in healthy adult volunteers, a category generally seen as lower risk than more complex early-stage studies. First-in-human trials are excluded, as are other higher-complexity or higher-risk applications, including studies involving advanced therapies, some devices or diagnostics, and certain complex trial designs. The MHRA said the pilot is intended to speed approvals for certain lower-risk Phase 1 studies while “maintain[ing] high safety and quality standards” and helping “boost the UK’s competitiveness in early-phase research.”

For drug developers, the practical significance is straightforward. The standard non-pilot timeline for a first assessment is 30 calendar days, so a faster regulatory review could shorten the time needed to start eligible studies in the UK. But regulatory clearance is not the only hurdle. The Health Research Authority, the body that oversees research ethics committee review in England, told sponsors to align applications with its fast-track ethics process so that a quicker MHRA decision is not canceled out by slower ethics approval. For many clinical trials, both regulatory and ethics approvals are needed before a study can begin.

The fast track also comes with operational limits. Participation is capacity-controlled, with slots allocated on a first-come, first-served basis and sponsors required to book before submitting. Maximum capacity rises through the year: one application per week in the first quarter, two per week by the end of the second quarter, three per week by the end of the third quarter and four per week by the end of the fourth quarter, equivalent to as many as 16 per month. The headline review timeline also does not begin the moment an application is filed. The MHRA said validation can take up to seven calendar days before the review clock starts, and warned that incomplete or poor-quality submissions may be removed from the pilot and lose their expedited slot.

The pilot sits within a broader regulatory overhaul. Amended UK clinical trials regulations took effect on April 28, 2026, creating a framework for faster, more risk-proportionate review. In a July 16 press release for its 2025-26 annual report, the MHRA said, “Looking ahead to 2026-27, the MHRA will implement new Clinical Trials Regulations, including a 14-day first assessment for phase 1 clinical trials.”

What the new guidance does not provide is evidence yet on how the pilot is performing. The MHRA sets out the process, eligibility rules and timetable, but it has not published data showing how many sponsors have used the scheme or whether any 14-day decisions have already been completed.